Generated: May 27, 2017
|Title:||Nor bis-indole compounds usable as medicaments|
|Abstract:||Compounds with antitumoral activity corresponding to the formula (I): ##STR1## wherein R'.sub.1 is a hydrogen atom or an alkoxy, acyl, formyl or haloacyl radical; R'.sub.2 is a hydrogen atom or an alkyl radical; R'.sub.3 and R".sub.3 are a hydrogen atom, hydroxyl radical or an alkanoyloxy radical, and together are a carbonyl group, and R'.sub.3 and R'.sub.5 together are an epoxy bridge or a double bond; R'.sub.4 is a hydrogen atom or an alkyloxycarbonyl, hydroxymethyl, alkanoyloxymethyl or acetamido radical; R'.sub.5 and R".sub.5 are a hydrogen atom or a hydroxyl, alkanoyloxyl, ethyl or 2-hydroxyethyl radical; R'.sub.6 is a hydrogen atom or an ethyl, 2-hydroxyethyl or acetyl radical; R.sub.1 is a hydrogen atom or an alkyl, formyl or acyl radical; R.sub.2 is a hydrogen atom or alkoxy radical; R.sub.3 is a hydrogen atom or a hydroxyl or alkanoyloxyl radical, and together with R.sub.4 is an epoxy bridge or a double bond; R.sub.4 is a hydrogen atom or a hydroxyl, alkanoyloxyl radical, and together with R.sub.5 is an epoxy bridge; R.sub.6 is an alkyloxycarbonyl, hydrazido, acetamido, hydroxymethyl or alkanoyloxymethyl radical; and R.sub.5 and R.sub.7 are a hydrogen atom or a hydroxyl and alkanoyloxyl radical; acid addition and quaternary ammonium salts thereof and 12-chloro derivatives thereof.|
|Inventor(s):||Langlois; Nicole (Bures S. Yvette, FR), Langlois; Yves (Bures S. Yvette, FR), Andriamialisoa; Ratremaniaina Z. (Les Ulis, FR), Potieo; Pierre (Bois d'Arcy, FR), Mangeney; Pierre (Paris, FR)|
|Assignee:||Agence Nationale de Valorisation de la Recherche (ANVAR) (Paris, FR)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0010458||► Subscribe||SPC/GB96/037||United Kingdom||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.